SEC Form 4 · accession 0001209191-15-078180
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amit Sachdev
Officer — EVP, Policy, Access & Value
Period of report
Oct 30, 2015
Accepted (ET)
Nov 3, 2015 · 6:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Oct 30, 2015 | S | 700 | $123.34 | D | 84,201 | D | |
| Common StockF2,F4 | Oct 30, 2015 | S | 1,500 | $124.94 | D | 82,701 | D | |
| Common StockF2,F5 | Oct 30, 2015 | S | 2,638 | $126.01 | D | 80,063 | D | |
| Common StockF2,F6 | Oct 30, 2015 | S | 1,100 | $126.61 | D | 78,963 | D | |
| Common Stock | holding | — | — | — | 882 | I | 401(k) |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.
- F2Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $123.34 (range $123.06 to $123.66).
- F4Open market sales reported on this line occurred at a weighted average price of $124.94 (range $124.40 to $125.37).
- F5Open market sales reported on this line occurred at a weighted average price of $126.01 (range $125.43 to $126.39).
- F6Open market sales reported on this line occurred at a weighted average price of $126.61 (range $126.44 to $126.75).